Search

Displaying results 6681 - 6690 of 7059 in total
  1. Drug

    MD05

    go.drugbank.com/drugs/DB06375
    Investigational

    MD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).

  2. Drug

    T611

    go.drugbank.com/drugs/DB06391
    Experimental

    T611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.

  3. Drug

    Clomethiazole

    go.drugbank.com/drugs/DB06470
    Investigational

    It is a drug which is structurally related to thiamine (vitamin B1) but acts like a sedative, hypnotic, muscle relaxant and anticonvulsant. … Clomethiazole is a well-established γ-aminobutyric acid (GABAA)-mimetic drug. It is a sedative and hypnotic that is widely used in treating and preventing symptoms of acute alcohol withdrawal.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Fradafiban

    go.drugbank.com/drugs/DB06472
    Experimental

  5. Drug

    Ruplizumab

    go.drugbank.com/drugs/DB06475
    Investigational

    Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.

  6. Drug

    FK352B

    go.drugbank.com/drugs/DB06484
    Experimental

    FK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.

    Synonyms: 2-((2R)-1-((2E)-3-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)PROP-2-ENOYL)PIPERIDIN-2-YL)ACETIC ACID, 2-PIPERIDINEACETIC ACID, 1-((2E)-1-OXO-3-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)-2-PROPEN-1-YL)-, (2R)-
  7. Drug

    ANA975

    go.drugbank.com/drugs/DB06490
    Experimental

    ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.

    Synonyms: THIAZOLO(4,5-D)PYRIMIDIN-2(3H)-ONE, 5-AMINO-3-(2,3-DI-O-ACETYL-.BETA.-D-RIBOFURANOSYL)-, ((2R,3R,4R,5R)-4-ACETOXY-5-(5-AMINO-2-OXO-THIAZOLO(4,5-D)PYRIMIDIN-3-YL)-2-(HYDROXYMETHYL)TETRAHYDROFURAN-3-YL) ACETATE
  8. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  9. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  10. Drug

    Atibuclimab

    go.drugbank.com/drugs/DB06546
    Investigational

    Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.